Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Source: Senate LDA
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for pleasdings and discovery in patent cases for both drugs and biologics
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including HR 1281 and S. 1417
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including HR 1281
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including HR 1281 and S. 1417
Support for reauthorization of the Prescription Drug User Fee Act (S. 3187/H.R. 5651) to: 1) Improve the transparency and predictability of the FDA drug review process. 2) Allow for modifications to the REMS program to improve communication and accuracy of information to providers and patients. 3) Expand existing FDA authority to allow for accelerated approval for products that address severe and life threatening diseases.
To correct and improve certain provisions of the Leahy-Smith America Invents Act and title 35, United States Code.
HR 6621 -- Opposition to provisions to amend the effective date of Uruguay Round Agreements Act (URAA) as it relates to certain patent applications.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to prohibition of patent settlements.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to prohibition of patent settlements.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
1) Biosimilars, including HR 3590 and HR 4872 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform (HR 3590 and HR 4872) -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
1) Biosimilars, including HR 3590 and HR 4872 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform (HR 3590 and HR 4872) -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Follow on Biologics, including HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Follow on Biologics, including S 1695, HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patient Protection and Innovative Biologic Medicines Act of 2007
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Patient Protection and Innovative Biologic Medicines Act of 2007
Follow on Biologics, including S 1695, HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Patient Protection and Innovative Biologic Medicines Act of 2007
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Patient Protection and Innovative Biologic Medicines Act of 2007
Follow on Biologics, including HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Patient Protection and Innovative Biologic Medicines Act of 2007
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Follow on Biologics, including HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Follow on Biologics, including S 1695, HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
1) Support 340B anti-fraud and program integrity policies; 2) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 3) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; and 4) Support policies that encourage and preserve scientific and medical innovation.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 3) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 4) Support policies that encourage and preserve scientific and medical innovation.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs; Support maintaining the orphan drug tax credit; and 3) Support maintaining and making permanent the Research & Development tax credit.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs; 2) Support maintaining the orphan drug tax credit; and 3) Support maintaining and making permanent the Research & Development tax credit.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates or price controls in the Medicare Part D program. 2) Opposition to changes to the Medicare Part B reimbursement system.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics
1) Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs. 2) Support maintaining the orphan drug tax credit. 3) Support maintaining and making permanent the Research and Development tax credit.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Opposition to rebates or price controls in the Medicare Part D program. 2) Opposition to changes to the ASP+6 Medicare Part B reimbursement system.
1) Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs. 2) Support maintaining the orphan drug tax credit. 3) Support maintaining the Research and Development tax credit.
1) Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs. 2) Support maintaining the orphan drug tax credit.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including HR 1281 and S. 1417
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to rebates or price controls in the Medicare Part D program. 2) Opposition to cuts to the Medicare Part B ASP +6 reimbursement formula.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates or price controls in the Medicare Part D program. 2) Opposition to cuts to the Medicare Part B ASP +6 reimbursement formula.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support 340B anti-fraud and program integrity policies.
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for reauthorization of the Prescription Drug User Fee Act (S. 3187/H.R. 5651) to: 1) Improve the transparency and predictability of the FDA drug review process. 2) Allow for modifications to the REMS program to improve communication and accuracy of information to providers and patients. 3) Expand existing FDA authority to allow for accelerated approval for products that address severe and life threatening diseases.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for reauthorization of the Prescription Drug User Fee Act (PDUFA V) to: 1) Improve the transparency and predictability of the FDA drug review process. 2) Allow for modifications to the REMS program to improve communication and accuracy of information to providers and patients. 3) Expand existing FDA authority to allow for accelerated approval for products that address severe and life threatening diseases.
Opposition to changes to Medicare Parts D and B reimbursement systems which could have adverse impact on patient access and US-based jobs.
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support for appropriate guidance, comment period, and implementation timelines as required by PL 111-148 Section 6002. 3) Oppose efforts to expand importation of prescription drugs without adequate safety standards and patient protections.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
Support for S. 23 and HR 1249, which modernize the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, fee diversion and post-grant/second window.
1) Opposition to changes to Medicare Parts D and B reimbursement systems which could have adverse impact on patient access and US-based jobs.
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support for reauthorization of the Prescription Drug User Fee Act (PDUFA V) to improve the FDA drug review process. 3) Support for appropriate guidance, comment period, and implementation timelines as required by PL 111-148 Section 6002.
Opposition to Medicare Part D rebates and/or rebates applied to dual eligibles.
1) Advocacy to reform IPAB to ensure patient access to medically necessary therapies. 2) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 3) Support for reauthorization of the Prescription Drug User Fee Act (PDUFA V) to improve the FDA drug review process.
Support corporate tax policies which protect US research and manufacturing jobs.
1) Implementation of biosimilars regulations to support incentives for innovation and second generation therapies. 2) Support for passage of the PDUFA reathorization to increase transparency and efficiency of the drug review process at FDA
Patent Reform -- S. 23 and HR 1249 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Advocacy to reform IPAB to ensure patient access to medically necessary therapies.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Support corporate tax policies which protect US research and manufacturing jobs, including issues related to transfer pricing and R&D credit.
1) Advocacy to reform IPAB to ensure patient access to medically necessary therapies. 2) Implementation of biosimilars regulations to support incentives for innovation and second generation therapies.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
Support corporate tax policies which protect US research and manufacturing jobs, including issues related to transfer pricing and R&D credit.
1) Advocacy to reform IPAB to ensure patient access to medically necessary therapies. 2) Health care reform: Implementation of the pharmaceutical manufacturer fee
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to prohibition of patent settlements.
Advocacy related to corporate tax policies, including repatriation, "deferral", "check the box", transfer pricing, and R&D credit.
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
1) Biosimilars, including HR 3590 and HR 4872 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform (HR 3590 and HR 4872) -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure eligible entities access 340b pricing for uninsured or underinsured patients.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window.
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
Advocacy related to corporate tax policies, including deferral and R&D credit.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Advocacy for appropriate reimbursement and payment rates for biologics under the Medicare and Medicaid programs.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
HR 1 -- Repatriation, deferral and R&D credit issues
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing stregnth and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation. 3) S. 301-- Advocating for reasonable gift disclosure requirments that provide appropriate transperancy and protects proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and opposed to using such research for cost containment or denial of coverage.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
1) Comparative effectiveness provisions -- supporting increased transparency/reporting requirements. 2) Physician gift disclosure provisions 3) Hospital Outpatient Prospective Payment System rule -- Oppose CMS proposal to reduce hospital outpatient reimbursment rates for certain pharmaceuticals from ASP +5 to ASP +4.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
1) Comparative effectiveness provisions -- supporting increased transparency/reporting requirements. 2) Physician gift disclosure provisions 3) Hospital Outpatient Prospective Payment System rule -- Oppose CMS proposal to reduce hospital outpatient reimbursment rates for certain pharmaceuticals from ASP +5 to ASP +4.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
1) Biosimilars, including S 1695, HR 1956, HR 1038, and HR 5629 -- Generating support for Committee/House consideration of legislation to creat a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protecting innovation.
1) Comparative effectiveness provisions -- supporting increased transparency/reporting requirements. 2) Physician gift disclosure provisions 3) Hospital Outpatient Prospective Payment System rule -- Oppose CMS proposal to reduce hospital outpatient reimbursment rates for certain pharmaceuticals from ASP +5 to ASP +4.
1) Comparative effectiveness provisions -- supporting increased transparency/reporting requirements. 2) Physician gift disclosure provisions
Follow on Biologics, including S 1695, HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Reform -- S. 1145 and HR 1908 provisions related to apportionment of damages, inequitable conduct, and post-grant/second window.
Initiatives to create comparative effectiveness studies within the Medicare program -- supporting increased transparency/reporting requirements.
Follow on Biologics, including HR 1956, HR 1038, and HR 5629. Generating support for Committee/House consideration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposal for payment of radiopharmaceuticals; comparative effectiveness
Follow On Biologics Legislation (HR 1956, HR 1038, S. 1695) and Comparative Effectiveness
Patent reform (H.R. 1908 and S. 1145)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Reform (HR. 1908 and S. 1145)
1) Follow-on Biologics (H.R. 1038/S. 623, H.R. 1956) 2) PDUFA/Drug Safety (S. 1082, H.R. 2900, Drug Safety Provisions) 3) AHRQ report ("The clinical effectiveness and cost effectiveness of interferon-beta and glatiramer acetate in the mgmt. of relapsing/remitting and secondary-progressive M.S.")
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), SENATE
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Opposition to rebates or price controls in the Medicare Part D program; and 2) Opposition to changes to the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement. 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for pleasdings and discovery in patent cases for both drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to rebates or price controls in the Medicare Part D program.
Patent legislation H.R. 3309, section 299A promoting appropriate rules for discovery in patent cases for both drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
1) Opposition to rebates or price controls in the Medicare Part D program. 2) Opposition to cuts to the Medicare Part B ASP +6 reimbursement formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program, including HR 1281
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support 340B anti-fraud and program integrity policies. 3) Support policies to improve National Newborn Screening Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 6621 -- Opposition to provisions to amend the effective date of Uruguay Round Agreements Act (URAA) as it relates to certain patent applications.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Support corporate tax policies which protect US research and manufacturing jobs. Support for repatriation tax holiday.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.
Patent Reform -- S. 23 and HR 1249 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, fee diversion and post-grant/second window.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
1) Support corporate tax policies which protect US research and manufacturing jobs, including issues related to US corporate tax rate, transfer pricing and patent box.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy related to corporate tax policies, including repatriation, "deferral", "check the box", and R&D credit.
Advocacy for appropriate reimbursement terms and payment rates for biologics under the Medicare and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy related to corporate tax policies, including "deferral", "check the box", and R&D credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Biosimilars, including HR 3200, S 1679, HR 1427, HR 1548 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation by ensuring reimbursement rates and payment/delivery systems provide full access to health care services, including: -- S 301-- Advocating for gift disclosure requirements that provide appropriate transparency and protect proprietary business information. -- HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes and in opposition to using such research for cost containment or denial of coverage. -- Opposition to price controls for pharmaceuticals, including expansion of 340b program pricing. Advocacy to ensure program applies only to entities serving a disproportionate share of patients seeking uncompensated care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy related to corporate tax policies, including deferral and R&D credit issues
Advocacy for appropriate reimbursement and payment rates for biologics under the Medicare and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy related to corporate tax policies, including deferral and R&D credit issues
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy for appropriate reimbursement and payment rates for biologics under the Medicare and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE